Trial Profile
Multicentre double blind placebo controlled parallel group dose ranging study of ATL-962 [cetilistat] to assess weight loss, safety and tolerability in obese patients with type II diabetes being treated with metformin, in comparison with orlistat
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Cetilistat (Primary) ; Orlistat
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Apr 2007 Results presented at the 15th European Congress on Obesity (ECO 2007).
- 28 Nov 2005 New trial record.